GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atea Pharmaceuticals Inc (NAS:AVIR) » Definitions » 5-Year ROIIC %

Atea Pharmaceuticals (Atea Pharmaceuticals) 5-Year ROIIC % : -3,051.20% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Atea Pharmaceuticals 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Atea Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -3,051.20%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Atea Pharmaceuticals's 5-Year ROIIC % or its related term are showing as below:

AVIR's 5-Year ROIIC % is ranked worse than
97.96% of 1373 companies
in the Biotechnology industry
Industry Median: -19.48 vs AVIR: -3051.20

Atea Pharmaceuticals 5-Year ROIIC % Historical Data

The historical data trend for Atea Pharmaceuticals's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atea Pharmaceuticals 5-Year ROIIC % Chart

Atea Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year ROIIC %
Get a 7-Day Free Trial - - - - -3,051.20

Atea Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -3,051.20 -

Competitive Comparison of Atea Pharmaceuticals's 5-Year ROIIC %

For the Biotechnology subindustry, Atea Pharmaceuticals's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atea Pharmaceuticals's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Atea Pharmaceuticals's 5-Year ROIIC % falls into.



Atea Pharmaceuticals 5-Year ROIIC % Calculation

Atea Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -165.393215 (Dec. 2023) - -9.477 (Dec. 2018) )/( 5.2729999999999 (Dec. 2023) - 0.163 (Dec. 2018) )
=-155.916215/5.1099999999999
=-3,051.20%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Atea Pharmaceuticals  (NAS:AVIR) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Atea Pharmaceuticals 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Atea Pharmaceuticals's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Atea Pharmaceuticals (Atea Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
225 Franklin Street, Suite 2100, Boston, MA, USA, 02110
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Executives
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Polly A. Murphy director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Jerome M. Adams director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp 10 percent owner 190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Jean-pierre Sommadossi director, 10 percent owner, officer: President, CEO, and Chairman 125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110
Jpm Partners Llc 10 percent owner C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Chung K. Chu 10 percent owner C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Janet Mj Hammond officer: Chief Development Officer C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Isaac Cheng director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
John Vavricka officer: Chief Commercial Officer C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Bruno Lucidi director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Maria Arantxa Horga officer: Acting Chief Medical Officer C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Bruce Polsky director C/O VISION-SCIENCES, INC., 40 RAMLAND ROAD, ORANGEBURG NY 10962

Atea Pharmaceuticals (Atea Pharmaceuticals) Headlines

From GuruFocus

Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-04-2023